top of page
Browse by category
Search
GLP-1 receptor agonist drugs are effective but come with complex concerns
Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective for weight management and Type 2 diabetes treatment,...
GLP-1 medications may lower risk of acute pancreatitis
Glucagon-like peptide-1 (GLP-1) receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those...
Study to analyse the real-world effectiveness of GLP-1 weight-loss drugs and inequities in access to these medications
The Robert Wood Johnson Foundation has awarded a grant to Andrew Stokes, associate professor of global health, Boston University School...
Dose-dependent link between the use of semaglutide and liraglutide injectables and body contouring procedures
There is a dose-dependent link between the use of injectable glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide and...
No association between suicidal, self-injurious thoughts and actions and GLP-1s
The available evidence does not support a causal association between the Glucagon-Like Peptide-1 receptor agonists (GLP-1) – dulaglutide,...
FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
GLP-1RAs may lead to increased risk of aspiration pneumonia following endoscopy
People who are scheduled for certain medical procedures should stop taking glucagon-like peptide-1 receptor agonists (GLP-1RAs)...
Medications for type 2 diabetes and weight loss poorly prescribed
Three independent, preliminary research studies have found that new type 2 diabetes and weight-loss medications are often not prescribed...
GLP-1s do not increase aspiration or pneumonia in surgery patients
There is no association between prescription glucagon-like peptide-1 (GLP-1) agonist medications and increased risk of aspiration or...
GLP1 agonists associated with a reduced risk of developing cirrhosis and liver cancer in people with T2DM and chronic liver disease
Glucagon-like peptide-1 receptor (GLP1) agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people...
Browse by tag
bottom of page